Cysteine-Modified AAV Capsids for Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adeno-associated virus (AAV) vectors face limitations such as immunogenicity, broad tropism, and reduced therapeutic index, leading to challenges in gene therapy, particularly in pediatric patients and tissues with preexisting neutralizing antibodies.
Innovation Solution
Chemically modifying cysteine residues in the AAV capsid with functional moieties like benzoyl acrylamide or maleimide groups to introduce specific ligands, thereby modulating tropism and transduction efficacy while maintaining infectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high dose of AAV is administered to achieve effective transduction, then transduction efficacy is improved, but immune response and induction of neutralizing antibodies increases
Solution Approach 1:
The patent applies local quality by introducing specific amino acid mutations at targeted locations on the AAV capsid surface (e.g., pHEP epitope residues). These localized mutations modify immune recognition properties without altering overall capsid structure or transduction function, thereby reducing immunogenicity while maintaining high transduction efficacy at lower doses.
Solution Approach 2:
The patent employs parameter changes by mutating specific amino acid residues in the pHEP epitope region of the AAV capsid. These parameter changes (amino acid substitutions) alter the immunogenic properties of the virus particle, reducing neutralizing antibody induction while preserving transduction capability, thus resolving the contradiction between efficacy and immune response.
2Duration of action of moving object
If AAV vector is re-administered to treat disease progression, then therapeutic effect is maintained, but preexisting neutralizing antibodies prevent transduction
Solution Approach 1:
The patent applies preliminary action by pre-modifying the AAV capsid with amino acid mutations that reduce immunogenicity before administration. This preliminary modification ensures that subsequent re-administrations can successfully transduce target cells despite preexisting neutralizing antibodies, enabling long-term therapeutic durability through multiple doses.
Solution Approach 2:
The patent uses inversion by reversing the conventional approach: instead of attempting to overcome neutralizing antibodies through high doses or alternative routes, the capsid itself is fundamentally modified to be resistant to neutralization. This inverted strategy makes the vector inherently capable of transducing cells even in the presence of preexisting antibodies.
3Adaptability or versatility
If AAV vector is designed with broad tropism for versatile application, then tissue targeting flexibility is improved, but transgene expression occurs in unintended tissues
Solution Approach 1:
The patent applies local quality by introducing specific amino acid mutations at defined locations on the AAV capsid surface that alter tissue tropism properties. These localized modifications enable selective targeting of specific tissues (e.g., liver, lung, muscle) while reducing uptake in unintended tissues, thereby resolving the contradiction between versatility and off-target expression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chemical modification of cysteine residues in the AAV capsid allows for targeted gene delivery with improved transduction efficiency and reduced immunogenicity, overcoming the limitations of unmodified AAV vectors.
Implementation Method 1
chemically modifying cysteine residues in the AAV capsid with functional moieties like benzoyl acrylamide or maleimide groups to introduce specific ligands
Data Source
AI summary
The invention relates to chemically modified adeno-associated (AAV) viruses and their use in gene therapy.